Wednesday, June 10, 2026

pharma Β· Eosinophilic esophagitis Β· Narcolepsy

Bioprojet

Bioprojet clinical programs β€” 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

9 rue Rameau, Paris, 75002, FR HQ
166 Employees
EMA registrant Type
Company details
Status
Public
HQ
9 rue Rameau, Paris, 75002, FR
Employees
166
Programs
11
Drugs
19
Patents
9
Intelligence Β· Clinical Programs

Bioprojet projects

4 ClinicalTrials.gov programs sponsored by Bioprojet.

Bioprojet has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Matches test product

    Bioprojet Pharma

    Essential tremor

    phase 2 small molecule active

    1 trial
  2. Matches test product

    Bioprojet Pharma

    Primary premature ejaculation

    phase 2 small molecule active

    1 trial
  3. Matching film-coated placebo tablet

    Bioprojet Pharma

    Obsessive compulsive disorder

    phase 2 small molecule active

    1 trial
  4. Matching orodispersible placebo tablet

    Bioprojet Pharma

    Eosinophilic esophagitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Bioprojet have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.